97279 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype Hinge
ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
#1202PSMA and CD3 bispecific T cell engaging antibody constructs
#1203Bispecific T cell engaging antibody constructs
#1204BCMA and CD3 bispecific T cell engaging antibody constructs
#1205ANTI-cMET ANTIBODY
#1206Immunoglobulin constant region Fc receptor binding agents
#1207TANDEM FC BISPECIFIC ANTIBODIES
#1208CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
#1209Antibodies that bind human cannabinoid 1 (CB1) receptor
#1210Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
#1211Tetravalent anti-PSGL-1 antibodies and uses thereof
#1212Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
#1213Genetic engineering of non-human animals for the production of chimeric antibodies
#1214Genetic engineering of non-human animals for the production of chimeric antibodies
#1215Genetic engineering of non-human animals for the production of chimeric antibodies
#1216Genetic engineering of non-human animals for the production of chimeric antibodies
#1217Genetic engineering of non-human animals for the production of chimeric antibodies
#1218Genetic engineering of non-human animals for the production of chimeric antibodies
#1219BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#1220Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
#1221Genetic engineering of non-human animals for the production of chimeric antibodies
#1222Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
#1223Antibody variants composition
#1224Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
#1225Drug regulated transgene expression
#1226Anti-HtrA1 antibodies and methods of use thereof
#1227Chimeric antigen receptor hCD87-CAR and applications thereof
#1228Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#1229CD33 specific chimeric antigen receptors for cancer immunotherapy
#1230Anti-DLL3 antibodies and drug conjugates for use in melanoma
#1231MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF
#1232Anti-CD28 humanized antibodies
#1233TEM8 ANTIBODIES AND METHODS OF USE
#1234Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
#1235Heavy chain only antibodies to ANG-2
#1236Methods and compositions for treating autoimmune and inflammatory conditions
#1237HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING VL DOMAINS
#1238Compositions for inhibiting MASP-2 dependent complement activation
#1239Multimeric Fc proteins
#1240REGULATABLE CHIMERIC ANTIGEN RECEPTOR
#1241Anti-PVRIG antibodies and methods of use
#1242MULTIMERIC FC PROTEINS
#1243Chimeric antigen receptor
#1244Heterodimeric proteins and methods for producing and purifying them
#1245Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke
#1246Antigen binding constructs to target molecules
#1247FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING
#1248FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES
#1249FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES
#1250Stable IgG4 antibodies
#1251MULTIMERIC FC PROTEINS
#1252Anti-PVRIG antibodies and methods of use
#1253Immunoconjugates with an intracellularly-cleavable linkage
#1254Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
#1255MULTISPECIFIC ANTIBODY ANALOGS COMPRISING A COMMON LIGHT CHAIN, AND METHODS OF THEIR PREPARATION AND USE
#1256Multispecific GITR-binding fusion proteins and methods of use thereof
#1257T-cell redirecting bispecific antibodies for treatment of disease
#1258Multivalent and multispecific DR5-binding fusion proteins
#1259Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#1260CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS
#1261Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
#1262FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#1263Anti-DLL3 antibody drug conjugates for treating cancer
#1264CSGP4 - Specific Chimeric Antigen Receptor for Cancer
#1265Hybrid constant regions
#1266Human CD3 binding antibody
#1267Variant target binding agents and uses thereof
#1268Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
#1269Immunoglobulin fusion proteins and uses thereof
#1270Method of using antibody polypeptides that antagonize CD40 to treat IBD
#1271Immunoglobulin constant region Fc receptor binding agents
#1272Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
#1273Antibodies comprising chimeric constant domains
#1274Selective reduction of proteins
#1275Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
#1276CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
#1277Multivalent antibodies
#1278Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#1279Humanized or chimeric CD3 antibodies
#1280Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
#1281Recombinant polypeptide production methods
#1282Chemically-Locked Bispecific Antibodies
#1283PDK1 BINDING MOLECULES AND USES THEREOF
#1284ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
#1285Bi-specific T-cell engager specific for BCMA
#1286Caninized antibodies
#1287DNA antibody constructs and method of using same
#1288Methods for treating cancer
#1289Anti-claudin antibodies and methods of use
#1290Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
#1291Human IgG1 derived antibody with pro-apoptotic activity
#1292Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#1293Targeting tissue factor to activated platelets
#1294Anti-PVRIG antibodies and methods of use
#1295Combination Therapy With Anti-CD74 and Anti-CD20 Antibodies Provides Enhanced Toxicity to B-Cell Diseases
#1296Epitope Spreading Associated with CAR T-Cells
#1297A METHOD FOR ANALYSING A SAMPLE IMMUNOGLOBULIN MOLECULES
#1298Method for producing polypeptide heteromultimer
#1299Anti-DLL3 antibody drug conjugates
#1300Method of targeting gene delivery using viral vectors
#1301Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
#1302MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1303Antibodies against PD-1 and uses thereof
#1304NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#1305Non-human mammals for the production of chimeric antibodies
#1306Non-human mammals for the production of chimeric antibodies
#1307Immunoconjugates with an intracellularly-cleavable linkage
#1308Non-human mammals for the production of chimeric antibodies
#1309Non-human mammals for the production of chimeric antibodies
#1310Non-human mammals for the production of chimeric antibodies
#1311Compositions and methods for treatment of cancer
#1312Anti-HIV domain antibodies and method of making and using same
#1313Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#1314ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT
#1315Compositions and methods for treatment of cancer
#1316Fusion proteins and their related methods
#1317Antibody locker for the inactivation of protein drug
#1318Cytotoxic immunoglobulin
#1319T-cell redirecting bispecific antibodies for treatment of disease
#1320Site-specific antibody conjugation methods and compositions
#1321Humanized or chimeric CD3 antibodies
#1322Anti-interleukin-33 antibodies and uses thereof
#1323Bispecific antibodies and methods for production thereof
#1324Antibody constant region variant
#1325ANTI-cMET ANTIBODY
#1326Covalent diabodies and uses thereof
#1327Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
#1328Antibodies and chimeric antigen receptors specific for CD19
#1329Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#1330Antibodies against CD73
#1331Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#1332Construction and application of bispecific antibody HER2xCD3
#1333Fc variants with improved complement activation
#1334IgG4 Fc fragment comprising modified hinge region
#1335Recombinant antibody composition
#1336Heteromultimers with reduced or silenced effector function
#1337Treatment of cancer using a CD33 chimeric antigen receptor
#1338Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1339Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1340Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF
#1341Construction and application of bispecific antibody EpCAM×CD3
#1342Production of antibody formats and immunological applications of said formats
#1343Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1344Immunoconjugates with an intracellularly-cleavable linkage
#1345Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1346Anti-C5 antibodies and methods of treating complement-related diseases
#1347Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1348HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
#1349Activated carbon filtration for purification of benzodiazepine ADCs
#1350Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
#1351TARGETING VACCINES FOR VETERINARY USE
#1352CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE
#1353Coiled coil and/or tether containing protein complexes and uses thereof
#1354Compositions for inhibiting MASP-2 dependent complement activation
#1355Antibody variants having modifications in the constant region
#1356Class I anti-CEA antibodies and uses thereof
#1357Inert format
#1358Monoclonal antibodies against c-Met
#1359Anti-PD1 antibodies and their use as therapeutics and diagnostics
#1360NOVEL ANTI-cMET ANTIBODY
#1361Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
#1362Vaccines against HPV
#1363FcgammaRIIB-specific Fc region variant
#1364Anti-cMET antibody
#1365COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES
#1366Human monoclonal anti-PD-L1 antibodies and methods of use
#1367Antibody constant region variant
#1368Methods and antibody compositions for tumor treatment
#1369PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY
#1370CD3 binding polypeptides
#1371Method for predicting efficacy of c-Met inhibitor
#1372Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#1373Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
#1374Peptide-hinge-free flexible antibody-like molecule
#1375Dimeric protein with triple mutations
#1376Cytotoxic immunoglobulin
#1377Artificial immunoglobulin fragment composition
#1378Serpin fusion polypeptides and methods of use thereof
#1379WAP domain fusion polypeptides and methods of use thereof
#1380Method of combination therapy using an anti-C-Met antibody
#1381Active protease-resistant antibody FC mutants
#1382Single-chain antibodies and other heteromultimers
#1383Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#1384Antigen binding constructs to CD3
#1385Serpin fusion polypeptides and methods of use thereof
#1386Anti-CD28 humanized antibodies
#1387Anti-CD40 antibody mutants
#1388VACCINES AGAINST HPV
#1389Immunoglobulin constant region Fc receptor binding agents
#1390Methods and compositions for inhibiting CD32B expressing cells
#1391Methods and compositions for inhibiting CD32b expressing cells
#1392Bispecific chimeric proteins comprising DARPins
#1393Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#1394Sequence symmetric modified IGG4 bispecific antibodies
#1395Sequence asymmetric modified IgG4 bispecific antibodies
#1396Molecules with extended half-lives, compositions and uses thereof
#1397FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#1398Method of target membrane protein depletion
#1399Nucleic acids encoding antibodies to CCR2
#1400Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
#1401Assembly of bispecific antibodies
#1402Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells
#1403Liquid formulation containing a protein drug
#1404Production of heterodimeric proteins
#1405Anti-idiotype antibody against anti-c-MET antibody
#1406Method of treating solid cancers using anti-c-Met antibody and sorafenib combination therapy
#1407Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment
#1408Hybrid constant regions
#1409Antibodies with modified isoelectric points
#1410Methods for treating transplant rejection by administering anti-CD40 antibody
#1411Bispecific T cell activating antigen binding molecules
#1412Polynucleotides encoding anti-CD40 antibodies
#1413Method for producing a multivalent fab fragment with collagen-like peptide
#1414Bispecific IgG antibodies as T cell engagers
#1415Variant target binding agents and uses thereof
#1416Immunoglobulin constant region FC receptor binding agents
#1417Methods of treating autoimmune disease with anti-CD40 antibodies
#1418Nucleic acids related to fusion proteins
#1419Molecules with antigen binding and polyvalent FC gamma receptor binding activity
#1420Expandable liquid volume in an LED bulb
#1421B-cell reduction using CD37-specific and CD20-specific binding molecules
#1422Binding molecules
#1423Binding molecules
#1424Serpin fusion polypeptides and methods of purification thereof
#1425Methods and compositions for inhibiting CD32B expressing cells
#1426Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
#1427Protein complexes for antigen binding and methods of use
#1428Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
#1429Monoclonal antibodies against c-Met
#1430ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#1431Homodimeric protein constructs
#1432Bispecific T-cell activator antibody
#1433Artificially produced polyclonal immunoglobulin preparation
#1434Binding domain-immunoglobulin fusion proteins
#1435Heterodimeric proteins and methods for producing and purifying them
#1436Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#1437Anti c-Met humanized antibody and uses thereof
#1438ANTI C-MET ANTIBODY AND USES THEREOF
#1439Molecules with extended half-lives, compositions and uses thereof
#1440Heterodimeric antibody Fc-containing proteins and methods for production thereof
#1441Engineered opsonin for pathogen detection and treatment
#1442Class I anti-CEA antibodies and uses thereof
#1443Expandable liquid volume in an LED bulb
#1444WAP domain fusion polypeptides and methods of use thereof
#1445Serpin fusion polypeptides and methods of use thereof
#1446COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE
#1447ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#1448Active protease-resistant antibody FC mutants
#1449Methods and compositions for inhibiting CD32B expressing cells
#1450IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#1451COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF
#1452Podocalyxin-like-protein-1 binding antibody molecule
#1453Multivalent Antibodies
#1454Compositions for inhibiting MASP-2 dependent complement activation
#1455Human growth hormone immunoglobulin fusion proteins
#1456Erythropoietin immunoglobulin fusion proteins
#1457G-CSF immunoglobulin fusion proteins
#1458IL-1 Binding Proteins
#1459IMMUNOGLOBULIN CLEAVAGE FRAGMENT VACCINE COMPOSITIONS
#1460Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#1461Modified antibody constant regions
#1462Immunoglobulin insertions, deletions, and substitutions
#1463Binding domain-immunoglobulin fusion proteins
#1464Expandable liquid volume in an LED bulb
#1465METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES
#1466TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS
#1467Methods and compositions for inhibiting CD32B expressing cells
#1468Methods and compositions for inhibiting CD32B expressing cells
#1469Methods and compositions for inhibiting CD32b expressing cells
#1470CD86 antagonist multi-target binding proteins
#1471Fusion proteins having mutated immunoglobulin hinge region
#1472HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS OR RENAL DISEASE ASSOCIATED ANEMIA
#1473Immunoconjugates with an intracellularly-cleavable linkage
#1474Antibody Constant Region Variant
#1475Antibody constant region variant
#1476Modulation of antibody effector function by hinge domain engineering
#1477FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES
#1478Single chain multivalent binding proteins with effector function
#1479Expandable liquid volume in an LED bulb
#1480Antibodies with modified isoelectric points
#1481Antibody variants composition
#1482Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1483Molecules with extended half-lives, compositions and uses thereof
#1484Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
#1485Antibody variants having modifications in the constant region
#1486Immunoconjugates with an intracellularly-cleavable linkage
#1487Antibodies to CCR2
#1488Process for the modulation of the antagonistic activity of a monoclonal antibody
#1489ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY COMPOSITIONS
#1490Anti-IL-6 Receptor Antibody
#1491Anti-CD40 antibodies
#1492Anti-cMet antibody
#1493Non-human mammals for the production of chimeric antibodies
#1494BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
#1495Method of targeted gene delivery using viral vectors
#1496MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1497Method of using fusion proteins
#1498Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
#1499Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
#1500Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof